[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100542191":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":33,"locations":39,"responsibleParty":57,"collaborators":10,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":10,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":10,"enrollmentInfo":68,"targetDuration":71,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":10,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Hospital Universitari de Bellvitge","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Indocianine Green (ICG)",null,"ICG tracer",[13],"Procedure: Targeted axillary dissection (TAD) by ICG",{"label":15,"type":10,"description":16,"interventionNames":17},"Blue patent","Blue patent tracer",[18],"Procedure: Targeted axillary dissection (TAD) by Blue patent",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"PROCEDURE","Targeted axillary dissection (TAD) by ICG","Use of ICG during the targeted axillary dissection (TAD)",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"Targeted axillary dissection (TAD) by Blue patent","Use of Blue patent during the targeted axillary dissection (TAD)",[15],[30],{"name":31,"affiliation":5,"role":32},"Carlos Ortega-Expósito","PRINCIPAL_INVESTIGATOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},"Amparo Garcia-Tejedor","CONTACT","0034-660223417","agarciat@bellvitgehospital.cat",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Hospital de Bellvitge","RECRUITING","L'Hospitalet de Llobregat","Barcelona","08907","Spain","ES",{"type":49,"coordinates":50},"Point",[51,52],2.10028,41.35967,{"lat":52,"lon":51},[55],{"name":56,"role":36,"phone":37,"phoneExt":10,"email":38},"Amparo Garcia-Tejedor, MDPhD",{"type":32,"investigatorFullName":35,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Principal Investigator","100542191","icg-vs-blue-patent-for-tad-in-cn1-breast-carcinoma-after-neoadjuvant-chemotherapy-100542191",false,"NCT06339658","ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy","ICG vs Blue Patent as a Tracer in the Performance of TAD in Patients With cN1 Breast Carcinoma After Neoadjuvant Chemotherapy","Inclusion Criteria:\n\n* Breast cancer cN+ patients who undergo neadjuvant treatment.\n\nExclusion Criteria:\n\n* Patients in whom there is a contraindication for the use of ICG.\n* Patients in whom there is evidence of progression of the disease after neoadjuvant treatment.","FEMALE","18 Years",{"count":69,"type":70},43,"ESTIMATED","2 Years","OBSERVATIONAL","To validate the use of ICG as a tracer during TAD in patients with cN1 breast carcinoma after neoadjuvant chemotherapy.",[75,76],"Breast Cancer","Axillary Metastases","2025-04-17",{"date":79,"type":80},"2025-04-22","ACTUAL",{"date":82,"type":80},"2021-01-01",{"date":84,"type":70},"2026-01-01",{"name":5,"class":6},1]